コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 asmosis, cryptosporidiosis, and Pneumocystis carinii pneumonia).
2 is patient had just completed therapy for P. carinii pneumonia.
3 igenic variation of P. carinii gpA during P. carinii pneumonia.
4 preferred choice for prophylaxis against P. carinii pneumonia.
5 7 patients enrolled, 298 had a history of P. carinii pneumonia.
6 ules CD2 and CD28 spontaneously developed P. carinii pneumonia.
7 y B cells in the context of recovery from P. carinii pneumonia.
8 t fourfold in BAL fluids of patients with P. carinii pneumonia.
9 lavage (BAL) fluids of humans with active P. carinii pneumonia.
10 found to vary during discrete episodes of P. carinii pneumonia.
11 he treatment and prophylaxis of Pneumocystis carinii pneumonia.
12 arinii f. sp. hominis should help prevent P. carinii pneumonia.
13 ion, scid mice developed uniformly severe P. carinii pneumonia.
14 d-immunosuppressed rat model of Pneumocystis carinii pneumonia.
15 one of the patients had cytomegalovirus or P carinii pneumonia.
16 pneumonia and 0.55 (P = 0.08) for primary P. carinii pneumonia.
17 itrexim in treatment of toxoplasmosis and P. carinii pneumonia.
18 osed to immunosuppressed mice with active P. carinii pneumonia.
19 rtunistic infections, including Pneumocystis carinii pneumonia.
20 ding 2 patients who died of non-Pneumocystis carinii pneumonia.
21 icting outcome in patients with Pneumocystis carinii pneumonia.
22 ) T cells infiltrate into the lung during P. carinii pneumonia.
23 ta-TCR(+) T cells in host defense against P. carinii pneumonia.
24 ight heart strain are common in Pneumocystis carinii pneumonia.
25 requent cause of admission than Pneumocystis carinii pneumonia.
26 onths and then died secondary to Pneumocytis carinii pneumonia.
27 ly suppress infection in animal models of P. carinii pneumonia.
28 y to respiratory failure during Pneumocystis carinii pneumonia.
29 S Treatment Center had a first episode of P. carinii pneumonia.
30 mphocytes and therefore develop Pneumocystis carinii pneumonia.
31 similarly effective for the prevention of P. carinii pneumonia.
32 eolar lavage specimens from patients with P. carinii pneumonia.
34 5% CI, 1.0-24), and to have had Pneumocystis carinii pneumonia (52.9% vs. 11.8%; OR, 7.6; 95% CI, 1.6
35 terium avium complex (73%), and Pneumocystis carinii pneumonia (69%), and the positive predictive val
36 ly dapsone (100 mg) for the prevention of P. carinii pneumonia among patients infected with the human
37 nt activity in the treatment of Pneumocystis carinii pneumonia, an opportunistic infection that is th
38 ve rates of 0.33 (P = 0.02) for secondary P. carinii pneumonia and 0.55 (P = 0.08) for primary P. car
40 e been studied in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome
41 ctrocardiogram in patients with Pneumocystis carinii pneumonia and AIDS in an attempt to identify ele
42 (SP-D) accumulate in the airspaces during P. carinii pneumonia and are particularly abundant in aggre
46 steroids are at greater risk of Pneumocystis carinii pneumonia and may benefit from prophylactic ther
47 ins isolated during different episodes of P. carinii pneumonia and supports the hypothesis that recur
48 tiation of antibiotic treatment for human P. carinii pneumonia and to immune reconstitution syndromes
50 urrent sinopulmonary infection, Pneumocystis carinii pneumonia, and Cryptosporidium parvum infection.
51 ces of cryptococcal meningitis, secondary P. carinii pneumonia, and herpes zoster decreased (P < 0.05
52 ansplanted mice, attenuation of Pneumocystis carinii pneumonia, and no evidence of lymphoproliferativ
53 Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii toxoplasmosis.
54 r cloacae, Serratia marcescens, Pneumocystis carinii pneumonia, and unknown (7%, 1 of 15) in one each
55 lthough the clinical aspects of Pneumocystis carinii pneumonia are well characterized, the basic biol
56 re was geographic clustering of Pneumocystis carinii pneumonia cases among patients with human immuno
57 mutations in patients with AIDS who have P. carinii pneumonia compares the change in the prevalence
58 ents studied, the incidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes z
59 /microL and was associated with Pneumocystis carinii pneumonia, cytomegalovirus meningoencephalitis,
60 d from pulmonary samples of patients with P. carinii pneumonia demonstrated that multiple MSG genes w
61 ing individuals at high clinical risk for P. carinii pneumonia) demonstrated the lowest levels of P.
63 oup, gender, race/ethnicity, certainty of P. carinii pneumonia diagnosis, age, region of residence, a
65 a, and included single cases of Pneumocystis carinii pneumonia, disseminated varicella zoster virus,
66 the incidence of bacterial and Pneumocystis carinii pneumonia each increased an average of 40% per y
68 itals and patients in hospitals with more P. carinii pneumonia-experience were also less likely to be
69 survival after the diagnosis of Pneumocystis carinii pneumonia for 19,607 patients in California in t
71 was measured, it predicted occurrence of P. carinii pneumonia (hazard ratio, 4.69 per 1og10 copies/m
73 and any possible use of immunotherapy for P. carinii pneumonia in humans must take into consideration
77 ompounds were effective against Pneumocystis carinii pneumonia in the immunosuppressed rat model with
78 dy response, IL-4(-/-) mice could resolve P. carinii pneumonia, indicating that resistance to P. cari
79 e of GM-CSF in host defense in a model of P. carinii pneumonia induced by intratracheal inoculation o
80 ful in other diseases including Pneumocystis carinii pneumonia, infection with Cryptococcus or Nocard
85 nd supports the hypothesis that recurrent P. carinii pneumonia is caused by reinfection rather than b
86 acute bronchitis, bacterial pneumonia and P. carinii pneumonia is high despite widespread chemoprophy
87 of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tolerate it and
88 lated immediately following recovery from P. carinii pneumonia, monoclonal antibodies (MAbs) were pro
90 major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease,
91 cute bronchitis, bacterial pneumonia, and P. carinii pneumonia occurred at high rates without discern
92 e influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific fac
94 and history of AIDS-defining illness, non-P. carinii pneumonia, oral thrush, or unexplained fever for
96 ine survival after diagnosis of Pneumocystis carinii pneumonia (PCP) and factors associated with earl
97 respiratory specimens from patients with P. carinii pneumonia (PCP) and from patients without clinic
99 odeficiency virus (HIV)-related Pneumocystis carinii pneumonia (PCP) and respiratory failure was poor
100 HPS) gene mutations in AIDS patients with P. carinii pneumonia (PCP) are affected by duration of sulf
101 gene mutations in patients with AIDS and P. carinii pneumonia (PCP) are associated with atovaquone e
104 With decreasing incidence of pneumocystis carinii pneumonia (PCP) in AIDS as a result of prophylac
105 evaluation as prodrugs against Pneumocystis carinii pneumonia (PCP) in an immunosuppressed rat model
109 We sought to determine the frequency of P carinii pneumonia (PCP) in patients with connective tiss
110 opportunistic fungal pathogen that causes P. carinii pneumonia (PCP) in the immunocompromised host.
112 ies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infants with HIV in
113 (TMP-SMZ) is the most effective Pneumocystis carinii pneumonia (PCP) prophylactic agent, but adverse
117 e recent declines in incidence, Pneumocystis carinii pneumonia (PCP) remains the most commonly occurr
118 neumocystis carinii in research models of P. carinii pneumonia (PCP) that is more convenient and repr
119 velopment of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated in the Adult a
120 n to protect mice from the development of P. carinii pneumonia (PCP) when they are subsequently immun
121 um avium complex (MAC) disease, Pneumocystis carinii pneumonia (PCP), and cytomegalovirus (CMV) retin
122 ratory infections, most notably Pneumocystis carinii pneumonia (PCP), but also bacterial pneumonia (B
123 agnosis of lung disease; 11 had Pneumocystis carinii pneumonia (PCP), one of whom was coinfected with
124 munodeficiency syndrome (AIDS)-associated P. carinii pneumonia (PCP), SIV-infected macaques were inoc
125 ontribute to lung injury during Pneumocystis carinii pneumonia (PCP), there are conflicting reports c
133 y-acquired pneumonia, including Pneumocystis carinii pneumonia (PCP; patients), and 192 matched HIV-i
134 table opportunistic infections (Pneumocystis carinii pneumonia [PCP] and disseminated Mycobacterium a
135 umocystis infection than CD4-depleted WT (P. carinii pneumonia [PCP] scores of 3 versus 2, respective
136 the setting of immune reconstitution and P. carinii pneumonia, pretreatment with the viral IL-10 gen
137 erapy (zidovudine) and the institution of P. carinii pneumonia prophylaxis (with cotrimoxazole and pe
138 le (TMP-SMX) is widely used for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency
139 ounts below 0.20 x 10(9)/L did not receive P carinii pneumonia prophylaxis, and 41% initially and 15%
140 ysis of the 24 zip code zones for which a P. carinii pneumonia rate was calculated (requiring a denom
143 ncidence rates of bacterial pneumonia and P. carinii pneumonia rise continuously during progression t
144 95% CI 1.43 to 2.76), and prior Pneumocystis carinii pneumonia (RR 3.88, 95% CI 1.65 to 9.16) were al
146 C3 patients who had a previous episode of P. carinii pneumonia showed a predominately Th2 response to
147 ements in survival after the diagnosis of P. carinii pneumonia, the long-term survival of these patie
148 rophylaxis is very effective in preventing P carinii pneumonia; the combination of trimethoprim-sulfa
149 T cells modulates host susceptibility to P. carinii pneumonia through interactions with pulmonary CD
150 stigated patients with HIV-1 infection and P carinii pneumonia to determine if DHPS mutations were as
152 of SP-D in host defense against Pneumocystis carinii pneumonia was assessed using SP-D knockout (KO)
153 us (HIV)-infected patients with confirmed P. carinii pneumonia was conducted in Atlanta, Seattle, and
158 Subjects included all cases for whom P. carinii pneumonia was the initial (and only) acquired im
159 Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protectio
161 C3 patients who had a previous episode of P. carinii pneumonia were compared with those who had not h
162 lavage (BAL) specimens from patients with P. carinii pneumonia were positive, whereas all 10 BAL spec
163 as well as from patients with and without P. carinii pneumonia, were reactive with this peptide by We
164 These mice were completely protected from P. carinii pneumonia when challenged by intratracheal inocu
165 A knockout mice developed uniformly heavy P. carinii pneumonia while wild-type mice cleared the P. ca
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。